<DOC>
	<DOCNO>NCT01487135</DOCNO>
	<brief_summary>The purpose study evaluate effect EVP-6124 therapeutic supratherapeutic concentration cardiac repolarization healthy subject .</brief_summary>
	<brief_title>Phase 1 Study Assess Effects EVP-6124 QT/QTc Interval Healthy Subjects</brief_title>
	<detailed_description>Subjects randomize six treatment sequence 10 subject . Subjects admit clinic Day -1 dose . Each EVP-6124 placebo treatment period ( blind ) include 10-day/9-night confinement Clinical Pharmacology Unit ( CPU ) study drug administer Day 1 Day 2 . The moxifloxacin treatment period ( open-label ) include 3-day/2-night confinement CPU moxifloxacin administration Day 1 . The study include 2 washout period washout start time last dose precede treatment period first dose next treatment period . The washout follow EVP-6124 placebo treatment 30 day washout follow moxifloxacin treatment 7 day . Follow-up visit ( 5 10 day follow discharge CPU ) .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Nonsmokers ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc 60 day prior administration study medication ) Physically mentally healthy volunteer Clinically significant electrocardiographic abnormality opinion Investigator History cardiovascular abnormalities/conditions include syncope 3 month precede enrollment history significant previous cardiac arrhythmia ; Potassium level outside normal range ( 3.5 5.2 mEq/L ) Clinically significant deviation normal blood pressure ( BP ) judge Investigator Currently , history , disease dysfunction pulmonary , cardiovascular , endocrine , hematologic , neurological , immune , gastrointestinal , genitourinary , body system , clinically significant opinion Investigator Unwilling refrain strenuous exercise 3 day prior baseline Day 1 discharge treatment period Family history Torsade de Pointes longQT syndrome , cardiac death sudden death without precede diagnosis condition could causative sudden death Evidence chronic medical condition require prescription medication History study drug allergy ( include moxifloxacin , likely hypersensitivity allergy EVP6124 , component EVP6124 ) Current history drug alcohol abuse within past year Abnormal preadmission clinical laboratory evaluation consider clinically significant Principal Investigator Any subject consider schedule undergo surgical procedure study Acute illness within 7 day prior study agent administration major illness hospitalization within 1 month prior study agent administration Any subject receive known hepatic renal clearance alter agent within 30 day prior first dose study drug A positive serology test human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody screen A positive urine drug screen ethanol substance abuse include cocaine , cannabinoids , phencyclidine , amphetamine , benzodiazepine , barbiturate , opiate , propoxyphene , methadone checkin ( ) Female subject childbearing potential positive serum pregnancy test screen baseline ( Day 1 ) treatment period . Sexually active female refuse take appropriate step become pregnant course clinical study Men , sexually active female partner childbearing potential , unwilling use appropriate contraception course study 30 day discharge last treatment period Donated plasma blood within 30 day prior first dose study medication history blood donation 450 mL within 3 month prior dose Use prescription medications/products , within 14 day prior dose administration Day 1 Treatment Period 1 , unless deem acceptable Investigator Use overthecounter , nonprescription preparation ( include mineral , phytotherapeutic/herbal/plantderived preparation ) , within 14 day prior dose administration Day 1 Treatment Period 1 , exception acetaminophen use recommended dos Use investigational drug 30 day prior Day 1 Treatment Period 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Thorough QT ( TQT )</keyword>
	<keyword>EVP-6124</keyword>
</DOC>